1. Scrip
  2. >>Business
  3. >>Strategy

Pharming Regains Rights To Ruconest, Seizing More Control Over Its Destiny

 
• By Sten Stovall

The European specialty pharma will pay $60m upfront to Valeant to reacquire the rights to commercialize the hereditary angioedema treatment in North America.

SC1608_Man-White-Board-Transaction_1200x675

Pharming NV has the opportunity to achieve profitability in 2017, three years sooner than expected by reacquiring the rights to commercialize its hereditary angioedema (HAE) treatment in North America, the firm said. The Netherlands-based specialty pharma announced Aug. 9 that it reached an agreement with Valeant Pharmaceuticals International Inc. to buy back rights to Ruconest (recombinant human C1 esterase inhibitor) in the US, Mexico and Canada for $60m upfront.

The deal will give Pharming control over the commercialization of Ruconest, which Valeant hadn’t been prioritizing given the recent upheaval at the company, including a change in leadership at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

Bayer Has BI In Its Sights With Priority Review For HER2 Lung Cancer Drug

 
• By Kevin Grogan

Sevabertinib gets onto the FDA's approval fast track three months after zongertinib.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Sun On Leqselvi US Launch Ahead, MFN Pricing And Pipeline Changes

 
• By Anju Ghangurde

Sun readies US debut of Leqselvi for alopecia areata, while PD-L1 inhibitor Unloxcyt is in the line up once the Checkpoint Therapeutics deal is completed. Management also discusses limited clarity on President Trump’s most favored nation pricing push, pipeline tweaks and M&A outlook.

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

More from Business

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

GlycoEra’s Series B Cash Will Fund Efforts To Take On FcRn Inhibitor Class

 
• By Joseph Haas

GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.